Report puts UK generics savings at up to 90%

An analysis commissioned by the British Generic Manufacturers Association (BGMA) has highlighted the extent of savings that copycat drugs bring to the UK’s National Health Service (NHS).

On average, generic selling prices over a four-year period after entry are 70%–90% lower versus the originator, says the study, carried out by economics consultancy Oxera.

The UK regulatory systems provide strong incentives to all key players to encourage generic medicines useThe number of generic prescriptions fulfilled by community pharmacy in England has doubled between 2005 and 2017 from £415 million ($526 million) to £824 million.